Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH).

View Full Paper
Ask AI
Bookmark
Share

Authors

BHBrittany HobbieACAmy ChadburnAKAdam S. Kittai

Discussion

Loading...

Member takes

Overview

Phase II study shows polatuzumab with chemoimmunotherapy achieves high remission rates in lymphoma, indicating effective treatment for richter transformation.

Key Points

  • To evaluate the efficacy and safety of polatuzumab in combination with chemoimmunotherapy for richter transformation.
  • Phase II clinical trial
  • Inclusion of patients with confirmed LBCL-RT
  • Combination therapy with polatuzumab and rituximab, etoposide, doxorubicin, cyclophosphamide, and prednisone
  • Evaluations based on Lugano 2014 criteria
  • Safety assessed using CTCAE version 4.3
  • Best overall response rate (ORR) was 83.3%
  • Complete remission (CR) rate was 50%
  • One year progression-free survival (PFS) was 70.9%
  • Most common adverse events included febrile neutropenia and infections
  • Encouraging activity in comparison to historical standards for treatment.

Cite This Study

Hobbie et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4d4https://doi.org/10.1182/blood-2025-3681
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase 2 trial of polatuzumab vedotin, rituximab and dose attenuated CHP in patients 75 years and older with large B-cell lymphoma2025
  2. 2Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study2025
  3. 3Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization2025
  4. 4Patient characteristics and treatment outcomes with Pola-R-CHP: A real-world study of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in the United States (US)2025 · 2 citations
  5. 5Real-world outcomes of polatuzumab, rituximab, and lenalidomide in frail pts with diffuse large B-cell lymphoma.2026